How should a 74-year-old woman with chronic sleep-maintenance insomnia, racing thoughts, mild untreated sleep apnea, and failure of multiple pharmacologic and over-the-counter sleep aids be managed?

{
  "question": "How should an elderly woman with chronic sleep-maintenance insomnia, racing thoughts, mild untreated sleep apnea, and failure of multiple pharmacologic and over-the-counter sleep aids be managed?"
}

---

Management Recommendation

This patient requires cognitive behavioral therapy for insomnia (CBT-I) as the primary intervention, with concurrent evaluation and treatment of her untreated sleep apnea, which may be perpetuating her insomnia.

Primary Treatment Approach

CBT-I is the first-line, standard-of-care treatment for chronic insomnia disorder in adults of all ages, including older adults, and should be initiated immediately 1, 2. The evidence supporting CBT-I is strong, with demonstrated efficacy sustained for up to 2 years in older adults 3. This patient has exhausted multiple pharmacologic options without benefit, making behavioral intervention even more critical.

Why CBT-I Takes Priority

• Guideline consensus: The 2017 AASM guideline provides a STRONG recommendation for multicomponent CBT-I as the treatment of chronic insomnia disorder 2
• Long-term efficacy: Unlike medications, CBT-I shows sustained benefits beyond the treatment period 4
• Safety profile: No risk of cognitive impairment, falls, or dependency—critical concerns in a 74-year-old 3
• Addresses perpetuating factors: Her "racing thoughts" and years-long pattern suggest psychophysiological insomnia with learned sleep-preventing associations that medications cannot address 4

Critical Comorbidity: Untreated Sleep Apnea

The mild untreated sleep apnea must be addressed concurrently, as this represents comorbid insomnia and sleep apnea (COMISA), which complicates treatment 5, 6, 7.

COMISA Management Strategy

1. Sleep apnea evaluation and treatment initiation:

   • Formal sleep study (PSG or home sleep apnea testing) to quantify severity 8
   • Initiate positive airway pressure (PAP) therapy if AHI ≥15 events/hour, or consider for mild OSA given her prominent insomnia symptoms 8
   • Critical pitfall: Untreated sleep apnea perpetuates insomnia and reduces treatment response 6, 7

2. Combined CBT-I + PAP approach:

   • CBT-I has been shown to improve PAP adherence in COMISA patients 5, 6
   • Treat both conditions simultaneously rather than sequentially 6, 7
   • Consider mandibular advancement device if PAP intolerance develops 5

Pharmacologic Considerations (Secondary Role)

Given her extensive medication failures, pharmacotherapy should play only an adjunctive role and only if CBT-I access is delayed or if residual symptoms persist after behavioral intervention 1.

What NOT to Continue

• Discontinue trazodone 200 mg: Insufficient evidence for efficacy in chronic insomnia, and she reports no benefit 1, 9
• Avoid benzodiazepines (she previously tried triazolam): Strong recommendation against use due to falls risk, cognitive impairment, and respiratory depression concerns in elderly patients with sleep apnea 9, 10
• Avoid quetiapine: She had a panic attack on this; antipsychotics carry serious harms including mortality risk in elderly populations 9
• Avoid over-the-counter antihistamines: Not recommended due to lack of efficacy, anticholinergic effects, and tolerance development after 3-4 days 1, 3

Limited Pharmacologic Options If Needed

If pharmacotherapy is deemed necessary as a temporary adjunct:

1. Low-dose doxepin (3-6 mg): FDA-approved for sleep maintenance insomnia; may be appropriate for her sleep-maintenance complaints 11, 10, 12

   • Caution: She's already tried multiple medications; assess if this represents a truly different mechanism

2. Dual orexin receptor antagonists (suvorexant): She previously tried suvorexant 5 mg—unclear if this was adequately dosed or trialed

   • Evidence shows improvement in sleep maintenance 1, 11, 1
   • May be better tolerated in COMISA than benzodiazepines 7
   • However: She's already failed this, suggesting limited utility

3. Short-term use only: Any pharmacotherapy should be time-limited (< 6 weeks nightly or as-needed basis) 13, 12

What About Her Previous Failures?

Her extensive medication trial history (lurasidone, zaleplon, ramelteon, suvorexant, quetiapine, triazolam, zolpidem, trazodone, OTC aids, marijuana) strongly suggests:

• Psychophysiological insomnia with significant behavioral perpetuating factors that medications cannot address 4
• Possible paradoxical insomnia component (misperception of sleep severity) 4
• Reinforcement of medication-seeking behavior rather than addressing core mechanisms

Specific Management Algorithm

Step 1: Immediate Actions

• Refer to behavioral sleep medicine specialist or psychologist for CBT-I (or digital CBT-I if in-person unavailable) 2
• Order sleep study to quantify sleep apnea severity 8
• Begin trazodone taper (no benefit reported at current dose)

Step 2: CBT-I Components to Implement

• Stimulus control therapy: Recommended as effective single-component therapy 2
• Sleep restriction therapy: Recommended as effective single-component therapy 2
• Cognitive restructuring: Address "racing thoughts" and anxiety about sleep 4
• Sleep hygiene: Useful when combined with other modalities, not as monotherapy 3, 2

Step 3: Sleep Apnea Treatment

• Initiate PAP therapy based on sleep study results 8
• Use telemedicine/remote monitoring to optimize adherence 8
• Address any PAP-related insomnia symptoms with CBT-I techniques 6

Step 4: Follow-up Schedule

• Week 1: Assess CBT-I engagement and PAP initiation
• Week 4: Evaluate treatment response using Insomnia Severity Index 4
• Month 3: Reassess symptoms; consider adjunctive pharmacotherapy only if significant residual symptoms despite adherent CBT-I and PAP use 1
• Every 6-12 months: Long-term monitoring 8

Common Pitfalls to Avoid

1. Continuing ineffective medications: Her trazodone provides no benefit—discontinue rather than increase further
2. Prescribing another hypnotic without behavioral intervention: This perpetuates the cycle and ignores guideline-based care 1
3. Ignoring the sleep apnea: COMISA requires treatment of both conditions 5, 6, 7
4. Using benzodiazepines in elderly patient with sleep apnea: Contraindicated due to respiratory depression and fall risk 9, 10
5. Expecting rapid medication response: Her years-long pattern requires behavioral restructuring, not another pill trial

Addressing Her Mood Concerns

Her "grumpiness," social withdrawal, and acknowledgment that she "may become depressed if sleep does not improve" warrant:

• Screening for major depressive disorder (though she currently denies depression)
• Recognition that persistent insomnia is a significant risk factor for developing mood disorders 1
• CBT-I addresses both insomnia and mood symptoms effectively 4

Evidence Quality Note

The strongest evidence (STRONG recommendations, moderate-quality evidence) supports CBT-I as first-line treatment 1, 2. Pharmacotherapy evidence is generally low-quality with small effect sizes 1, 11, 1. The 2016 American College of Physicians guideline found insufficient evidence for benzodiazepines, trazodone, and melatonin specifically 1, 11.

Bottom line: This patient needs behavioral intervention and sleep apnea treatment, not another medication trial.